Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan in early COVID-19 for high-risk or elderly patients
NL-OMON50002Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of telmisartan in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite of death or hospital admission. Planned start Nov 2020; status: withdrawn.
02
Drugs
telmisartan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50002.